New Haven drug developer Achillion Pharmaceuticals Inc. says it has moved into Phase 2 of its clinical trial for an effective treatment for chronic hepatitis.
The bioscience firm has begun dosing 60 patients in the U.S. and Europe for 12 weeks in the second segment of its trial of ACH-1625 for the treatment of hepatitis C virus. Results will be announced in the fourth quarter.
Achillion’s small-molecule treatment aims to short-circuit the virus’ ability to replicate.
Achillion is due to net at least $53 million from its latest equity offering of 10.35 million shares of common stock when it closes on Tuesday.
